Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
The American Review of Public Administration ; 2020.
Article | WHO COVID | ID: covidwho-670378

ABSTRACT

Although there have been studies investigating the relationship between information disclosure and voluntary compliance behaviors, the terrain of such research is largely fragmented and has been rarely tested empirically in the pandemic contexts This article reviewed the intervention and control of the pandemic from the perspective of information disclosure with reflections on the experience in China Furthermore, the authors propose a comprehensive framework demonstrating the overall landscape of information disclosure and voluntary compliance behaviors with highlights on (a) the tensions between privacy and information transparency;(b) the trade-offs between policy rigorousness and compliance behaviors;(c) different sources of information and how they influence public behaviors differently;and most importantly, (d) how the variegated configurations and contextualization of factors result in different influencing and moderating mechanisms between information disclosure and voluntary compliance behaviors In the end, the authors call for future research and reforms in pandemic control practice to focus on the dynamics of information disclosure, government actions, and public compliance behaviors, which has been largely neglected so far

2.
International Journal of Sociology ; 2020.
Article | WHO COVID | ID: covidwho-630143
3.
Allergy ; 75(7): 1742-1752, 2020 07.
Article in English | MEDLINE | ID: covidwho-27762

ABSTRACT

BACKGROUND: The clinical characteristics of novel coronavirus disease (COVID-2019) patients outside the epicenter of Hubei Province are less understood. METHODS: We analyzed the epidemiological and clinical features of all COVID-2019 cases in the only referral hospital in Shenzhen City, China, from January 11, 2020, to February 6, 2020, and followed until March 6, 2020. RESULTS: Among the 298 confirmed cases, 233 (81.5%) had been to Hubei, while 42 (14%) did not have a clear travel history. Only 218 (73.15%) cases had a fever as the initial symptom. Compared with the nonsevere cases, severe cases were associated with older age, those with underlying diseases, and higher levels of C-reactive protein, interleukin-6, and erythrocyte sedimentation rate. Slower clearance of the virus was associated with a higher risk of progression to critical condition. As of March 6, 2020, 268 (89.9%) patients were discharged and the overall case fatality ratio was 1.0%. CONCLUSIONS: In a designated hospital outside Hubei Province, COVID-2019 patients could be effectively managed by properly using the existing hospital system. Mortality may be lowered when cases are relatively mild, and there are sufficient medical resources to care and treat the disease.


Subject(s)
Betacoronavirus/genetics , Coronavirus Infections/epidemiology , Coronavirus Infections/physiopathology , Pneumonia, Viral/epidemiology , Pneumonia, Viral/physiopathology , Adolescent , Adult , Age Factors , Antiviral Agents/therapeutic use , Blood Sedimentation , C-Reactive Protein/analysis , Child , China/epidemiology , Coronavirus Infections/blood , Coronavirus Infections/drug therapy , Female , Hospitalization , Humans , Interleukin-6/blood , Male , Middle Aged , Pandemics , Pneumonia, Viral/blood , Pneumonia, Viral/drug therapy , Retrospective Studies , Risk Factors , Treatment Outcome , Young Adult
4.
Clin Infect Dis ; 2020 Mar 28.
Article in English | MEDLINE | ID: covidwho-17886

ABSTRACT

BACKGROUND: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. METHODS: A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed. RESULTS: Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then IgG were day-11, day-12 and day-14, separately. The presence of antibodies was <40% among patients within 1-week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) since day-15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) during day 15-39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (p<0.001), even in early phase of 1-week since onset (p=0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p=0.006). CONCLUSIONS: The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.

SELECTION OF CITATIONS
SEARCH DETAIL